But, like Merck two weeks ago, GSK has failed to hit overall survival.
ApexOnco Front Page
Recent articles
Two Kelun ADCs and two actinium-based radioconjugates start phase 1.
There’s little to distinguish the two HIF2α inhibitors in kidney cancer.
ZL-1310 looks better than other DLL3-targeting agents, but two thirds of responses are so far unconfirmed.
The focus for divarasib in second-line lung is now the head-to-head Krascendo-1 trial.
First-in-human study starts include radioligands from Akiram and Philogen.
A tie-up with LaNova was terminated, perhaps in favour of a molecule originated by I-Mab.
The French group takes a shot at Perspective with its second bet on Orano Med.
